An interventional study of Combined Functional Near-infrared Spectroscopy and Electroencephalography System and MRI Imaging in Stroke, Stroke (6 Months or More After Onset) and Stroke Gait Rehabilitation, sponsored by Aix Marseille Université. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Aix Marseille Université · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 545 studies in Stroke with a site in France — 143 open to participants now, 162 under way, 12 of them phase 3. Stroke · France.
Among the 545 studies in Stroke with a site in France, this one is the 233rd largest by planned enrollment of the 370 interventional ones that give a count, is one of 32 that started in 2026, is one of 277 with no phase, reaches primary completion later than 146 of the 161 other live ones, and was the 545th registered.
8,279 studies on the registry are indexed under Stroke; 2,067 are open to participants now.
Browse Stroke studies →143 of the 545 studies in Stroke with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18–80
University Hospital, Bordeaux · Sites in France
Ages 18+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Lille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,421 Stroke studies recruiting now, 696 (49%) set no upper age limit and 284 (20%) stop at 75 or younger; 77 take children under 18; 198 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
545 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 28 · Phase 3 52 · Phase 4 17
First in 1998; this study’s year is marked. 32 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 49 across 6,043 interventional studies indexed under Stroke.
Median enrollment 64 across the 370 interventional studies, 180 across the 173 observational. Of the 331 that completed or were terminated, 30 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 545 have an industry lead sponsor. The 10 most frequent:
Aix Marseille Université is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Aix Marseille Université has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
49 of the studies in Stroke with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03998852Phase 3University Hospital, BordeauxIn Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy. | 2027-04-13 |
| NCT06059144Phase 3University Hospital, BordeauxInduced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine | 2027-08-28 |
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT00759304Centre Hospitalier Universitaire de Saint EtienneEvaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events | 2026-12 |
Add all 49 to your calendar (.ics) → With an account.
Among the 545 studies in Stroke with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Stroke is a leading cause of long-term disability in adults. Many people who have had a stroke continue to experience difficulty walking because of muscle weakness and spasticity, which can limit their mobility and quality of life.
Botulinum toxin injections are commonly used to reduce spasticity in specific muscles, such as the calf muscles. Rehabilitation is then used to improve walking ability. Robot-assisted gait rehabilitation allows patients to practice walking intensively and repeatedly, with assistance adjusted to their needs. Previous research from our team has shown that robot-assisted gait rehabilitation may improve walking ability more than conventional physical therapy when combined with botulinum toxin injections.
The purpose of this study is to better understand why robot-assisted gait rehabilitation may be more effective than conventional gait rehabilitation after botulinum toxin treatment in people with chronic stroke. The study will examine changes in walking patterns, muscle activity, and brain activity during and after rehabilitation. Brain activity and brain connections will be assessed using non-invasive methods, including functional near-infrared spectroscopy (fNIRS), electroencephalography (EEG), and magnetic resonance imaging (MRI).
The study may help identify how the brain and body adapt to rehabilitation and may contribute to developing more personalized rehabilitation programs for people living with long-term effects of stroke.
Stroke is a major cause of acquired motor disability in adults. In the chronic phase after stroke, persistent motor impairment is frequently associated with spastic paresis, altered motor control, and maladaptive or compensatory reorganization of the central nervous system. Spasticity may contribute substantially to gait impairment and reduced mobility, thereby affecting functional independence and quality of life.
Botulinum toxin type A (BoNT-A) is an established treatment for focal spasticity after stroke. Intramuscular injection into the triceps surae reduces excessive muscle activity through its action at the neuromuscular junction and can temporarily improve the mechanical conditions for walking. In addition to these peripheral effects, BoNT-A may also indirectly influence central motor networks by modifying proprioceptive and afferent sensory input, potentially promoting cortical reorganization.
Following BoNT-A injection, intensive rehabilitation is required to optimize functional recovery. Robot-assisted gait rehabilitation provides a means of delivering intensive, repetitive, task-specific gait practice, with partial body-weight support and adjustable motor assistance. This approach may allow patients to perform a greater number of gait cycles and to train at higher walking speeds than conventional gait therapy. Previous studies have suggested that robot-assisted gait rehabilitation may improve gait performance, propulsion, gait symmetry, and motor coordination. In a previous study conducted by our research team, robot-assisted gait rehabilitation performed after BoNT-A injection into the triceps surae resulted in a significantly greater improvement in 6-minute walk distance than conventional gait rehabilitation.
The present study aims to investigate the neurophysiological and biomechanical mechanisms underlying the potentially greater benefit of robot-assisted gait rehabilitation compared with conventional gait rehabilitation following BoNT-A treatment in individuals with chronic stroke.
The study will characterize changes in gait performance and gait biomechanics, including spatiotemporal parameters, lower-limb joint kinematics, ground reaction forces, propulsion, and muscle activation patterns. These measurements will be used to determine whether specific changes in gait mechanics and neuromuscular coordination are associated with the greater improvement observed following robot-assisted rehabilitation.
In parallel, the study will investigate changes in brain activity and functional organization associated with rehabilitation. Functional near-infrared spectroscopy (fNIRS) will be used to assess cortical activation during walking. Electroencephalography (EEG) will be used to characterize cortical electrical activity and functional connectivity, with particular attention to changes in frontoparietal and motor networks. Resting-state functional magnetic resonance imaging (fMRI) and diffusion MRI will be used to assess functional and structural brain connectivity, respectively, as well as lesion characteristics and the organization of motor networks.
A particular focus will be placed on changes in the lateralization and organization of motor cortical activity following rehabilitation. The study will test the hypothesis that robot-assisted gait rehabilitation induces more effective neuroplastic adaptations than conventional gait rehabilitation after BoNT-A treatment. These adaptations are expected to involve a shift toward more efficient recruitment and functional organization of ipsilesional motor regions, together with changes in interhemispheric and network-level connectivity.
The study will also investigate whether central effects of BoNT-A can be detected through changes in cortical activity, including modifications of ipsilesional posterior parietal cortex activity previously reported after BoNT-A treatment.
By combining complementary neurophysiological, neuroimaging, biomechanical, and clinical measures, the study aims to identify mechanisms associated with improved walking recovery after BoNT-A combined with robot-assisted gait rehabilitation. An additional objective is to identify quantitative biomarkers that may help predict which individuals are most likely to benefit from this rehabilitation strategy and, ultimately, contribute to more individualized rehabilitation approaches for people with chronic post-stroke motor impairment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive robot-assisted gait rehabilitation following botulinum toxin type A injection into the triceps surae. The intervention consists of intensive, repetitive gait training using a robotic device, with adjustable assistance and body-weight support as appropriate.
Other: Combined Functional Near-infrared Spectroscopy and Electroencephalography System · Other: MRI Imaging · Behavioral: 6-Minute Walk Test · Behavioral: Muscle Strength Scale · Behavioral: Berg Balance Scale
Participants receive conventional gait rehabilitation following botulinum toxin type A injection into the triceps surae. The intervention consists of therapist-guided gait training and conventional physical therapy according to standard clinical practice.
Other: Combined Functional Near-infrared Spectroscopy and Electroencephalography System · Other: MRI Imaging · Behavioral: 6-Minute Walk Test · Behavioral: Muscle Strength Scale · Behavioral: Berg Balance Scale
Motor area connectivity during walking will be assessed using a combined functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) system. Each fNIRS/EEG assessment will consist of three repetitions of a rest-task-rest block (30-60-30 seconds). During the task period, participants will walk overground along a walkway at a self-selected comfortable speed.
Also known as: EEG, fNIRS
The 3T MRI protocol will include an anatomical MRI scan to localize the stroke lesion and assess its size, a resting-state functional MRI (rs-fMRI) to characterize the resting-state functional connectome, and a diffusion-weighted MRI to characterize the structural connectome.
Also known as: MRI, Magnetic resonance imaging
Participants will be asked to walk as far as possible for 6 minutes along a designated walking course at their self-selected pace. The total distance walked will be recorded as a measure of walking endurance and functional mobility.
Also known as: 6MWT
Muscle strength will be assessed using the Medical Research Council (MRC) scale. This clinical assessment grades muscle strength on a 0-to-5 scale, with higher scores indicating greater muscle strength.
Also known as: MRC Scale
Balance will be assessed using the Berg Balance Scale, a clinical assessment consisting of 14 functional tasks evaluating static and dynamic balance. Each item is scored from 0 to 4, with higher scores indicating better balance performance and a lower risk of falls.
Also known as: BBS
Difference in the Lateralization Index of Nodal Degree in the Paracentral Lobules
The primary outcome measure is the between-group difference in the organization of motor functional brain networks following botulinum toxin type A (BoNT-A) treatment of spasticity in the triceps surae, comparing robot-assisted gait rehabilitation with conventional gait rehabilitation. At rest, functional brain network organization will be assessed using resting-state functional magnetic resonance imaging (rs-fMRI). The primary resting-state parameter will be the lateralization index (Lik) of nodal degree (k) in the paracentral lobules ipsilateral and contralateral to the stroke lesion. The Lik will be used to quantify the relative distribution of nodal connectivity between the two hemispheres.
Time frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
Difference in the Lateralization Index of Activation in the Sensorimotor Cortex Derived From fNIRS Data
The lateralization index of cortical activation in the sensorimotor cortex will be calculated from functional near-infrared spectroscopy (fNIRS) data collected during walking. The outcome measure will assess the difference in the lateralization of sensorimotor cortical activation between robot-assisted gait rehabilitation and conventional gait rehabilitation following botulinum toxin type A treatment of spasticity in the triceps surae. Higher or lower lateralization index values will indicate a relative predominance of activation in one cerebral hemisphere.
Time frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
Lateralization of Brain Activation in Locomotor-Related Cortical Areas During Walking
The lateralization of brain activation in cortical areas involved in locomotion, including the prefrontal cortex (PFC), premotor cortex (PMC), and supplementary motor area (SMA), will be assessed during walking using functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG). Differences in the lateralization of cortical activation between the robot-assisted gait rehabilitation and conventional gait rehabilitation groups will be evaluated following botulinum toxin type A treatment of spasticity in the triceps surae.
Time frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
Change in Resting-State Activity of the Ipsilesional Posterior Parietal Cortex
Resting-state functional magnetic resonance imaging (rs-fMRI) will be used to assess changes in activity of the posterior parietal cortex ipsilateral to the stroke lesion. The change in resting-state activity will be compared between the robot-assisted gait rehabilitation and conventional gait rehabilitation groups following botulinum toxin type A treatment of spasticity in the triceps surae.
Time frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jun 2029, 30 months later.
Of 3,120 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 30 months is above that.
Counting every sponsor, half of 3,264 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aix Marseille Université